SAN CARLOS, Calif. (December 5, 2005) – Conceptus, Inc. (Nasdaq: CPTS), developer of the Essure® non-incisional permanent birth control system, today announced that Greg Lichtwardt, executive vice president and chief financial officer of Conceptus, will be presenting at the Harris Nesbitt Focus on Healthcare Conference. The presentation will take place on Thursday, December 8, 2005 at 3:15 pm Eastern Standard Time (EST) at the Millennium Broadway Hotel in New York City. Mr. Lichtwardt’s presentation will be in Room 508.

A link to the live webcast and the recorded webcast will be posted prior to the presentation in the investor relations section of the Company’s website at www.conceptus.com. The presentation will be archived for a limited time.

About the Essure Procedure
The Essure procedure deploys a soft micro-insert into the fallopian tube through the cervix using a minimally invasive transcervical tubal access catheter. Once in place, the device is designed to elicit tissue growth in and around the micro-insert to form an occlusion or blockage in the fallopian tube. An Essure procedure does not require cutting or penetrating the abdomen and can be performed in a less costly procedure setting without general anesthesia. A woman is able to return home about 45 minutes after the procedure is completed. There is a three-month waiting period after the procedure during which women must use another form of birth control. The Essure procedure is 99.80 percent effective after four years of follow-up. The Essure procedure has been demonstrated in a small portion of the women undergoing clinical studies to be 99.74 percent effective based on five years of follow-up. Five-year follow-up of all patients in clinical trials is ongoing.

About Conceptus Incorporated
Conceptus, Inc. manufactures and markets the Essure Permanent Birth Control system, an innovative medical device and procedure designed to provide a non-incisional alternative to tubal ligation, which is currently the leading form of birth control worldwide. The availability of the Essure procedure in the U.S. is expected to open up a market currently occupied by incisional tubal ligation and vasectomy, which combined account for over 1 million procedures annually.

Additional information about the Essure procedure is available at www.essure.com or by calling the Essure Information Center at 1-877-ESSURE1. Additional information about Conceptus is available at www.conceptus.com or by calling 1-877-ESSURE2.